First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
CNBC••general
Key Points:
- Novo Nordisk is launching the first-ever GLP-1 oral pill for weight loss, Wegovy, in the U.S. starting Monday, shortly after FDA approval on December 22.
- The Wegovy pill's cash prices range from $149 to $299 per month, significantly lower than the roughly $1,000 monthly list price for weekly injectable weight loss drugs, potentially improving affordability and access.
- The starting 1.5 mg dose is available at over 70,000 pharmacies and select telehealth providers, with higher doses becoming available by the end of the week; insured patients may pay as little as $25 monthly.
- Novo Nordisk's pill, which mimics the gut hormone GLP-1 to suppress appetite,
